

May 6, 2019



VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

Conference call to take place Thursday, May 9, 2019 at 8:30 am Eastern time

AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Thursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2019 in addition to providing a business update.

Event: VolitionRx Limited First Quarter 2019 Earnings and Business Update Conference Call

Date: Thursday, May 9, 2019

Time: 8:30 a.m. Eastern time

U.S. & Canada Dial-in: 1-855-327-6837 (toll free)

U.K. Dial-in: 0 808-101-2791 (toll free)

Toll/International: 1-631-891-4304

Conference ID: 10006803

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition's activities, including details of new and ongoing clinical trials, important events that have taken place in the first quarter of 2019, and milestones for the remainder of 2019 and beyond.

A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at <http://ir.volitionrx.com>. In addition, a telephone replay of the call will be available until May 23, 2019. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 10006803.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition's research and development activities are currently centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

Nucleosomics™ is a trademark of Volition and its subsidiaries.

For more information about Volition, visit Volition's website (<http://www.volitionrx.com>) or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Batchelor, Volition mediarelations@volitionrx.com +44 (0)7557 774620	Scott Powell, Volition investorrelations@volitionrx.com +1 (646) 650 1351
Joseph Green, Edison Advisors jgreen@edisongroup.com +1 (646) 653 7030	

 View original content: <http://www.prnewswire.com/news-releases/volitionrx-limited-schedules-first-quarter-2019-earnings-conference-call-and-business-update-300844501.html>

SOURCE VolitionRx Ltd